Mesalazine controlled release - Ferring

Drug Profile

Mesalazine controlled release - Ferring

Alternative Names: Mesalamine granules - Ferring; Pentasa; Pentasa® controlled release 500mg tablets; Pentasa® prolonged release granules 1g/2g/4g; Pentasa® Sachet; Pentasa® slow release 1g tablets; PS-QD

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Ferring Pharmaceuticals
  • Developer Ferring Pharmaceuticals; Kyorin Pharmaceutical; Shire US
  • Class Aminosalicylic acids; Anti-inflammatories; Irritable bowel syndrome therapies; Small molecules
  • Mechanism of Action Lipoxygenase-cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 01 Oct 2015 Phase-III clinical trials in Ulcerative colitis in Ukraine, Russia, Canada and Hungary (PO) after October 2015 (NCT02522780)
  • 19 Aug 2015 Ferring Pharmaceuticals plans a phase III trial for Ulcerative Colitis in USA, Belgium, Czech Republic, Hungary, Poland, Slovakia, Canada, Israel, Russia, Switzerland and Ukraine (PO, once-daily granules 2g ) (NCT02522780)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top